Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics dosed the first patient in EQUINOX-HFpEF, a Phase 2 trial of its oral cardiac sarcomere modulator EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction. The multicenter, randomized, double-blind, placebo-controlled study will enroll roughly 90 adults aged 30 to 84 with LVEF of at least 50%, testing once-daily 25 mg or 50 mg doses for up to 12 weeks.
Key figures
- Drug Name
- EDG-15400
- Phase Of Trial
- Phase 2
- Doses
- ["25 mg once daily","50 mg once daily","placebo"]
- Indication
- symptomatic HFpEF with LVEF ≥ 50%, NYHA class II-III
- Trial name
- EQUINOX-HFpEF
- Planned enrollment
- ~90 adults aged 30-84
- Treatment duration
- up to 12 weeks
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.